sb 203580 has been researched along with Prostatic Neoplasms in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (68.42) | 29.6817 |
| 2010's | 5 (26.32) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Henne, WA; Kularatne, SA; Low, PS; Santhapuram, HK; Vaitilingam, B; Venkatesh, C; Wang, K | 1 |
| Abou-Kheir, W; Bahmad, HF; Ballout, F; Daouk, R; Kadara, H; Monzer, A; Saleh, E | 1 |
| Bruzzese, F; Budillon, A; Capone, F; Caraglia, M; Carbone, C; Costantini, S; Di Gennaro, E; Leone, A; Milone, MR; Piro, G; Pucci, B | 1 |
| Cai, F; Guo, L; Liu, X; Xu, P | 1 |
| Gao, HW; He, YY; Khan, M; Li, YM; Ma, TH; Yang, JB; Yao, M | 1 |
| Chen, J; Du, T; Guo, Z; Huang, H; Lin, T; Wang, W; Xu, K; Zhang, Y | 1 |
| Kurland, JF; McDonnell, TJ; Meyn, RE; Munshi, A; Sah, NK; Su, B | 1 |
| Bergan, RC; Hayes, SA; Huang, X; Kambhampati, S; Platanias, LC | 1 |
| Chen, L; Fang, WG; Heng, WJ; You, JF | 1 |
| Chen, L; Fang, WG; He, HY; Heng, WJ; Li, HM; Li, Y; You, JF | 1 |
| Bergan, RC; Chen, S; Xu, L | 1 |
| Fuessel, S; Kunze, D; Meye, A; Schmidt, U; Wirth, MP | 1 |
| Aller, P; Fernández, C; Fraile, B; García-Tuñón, I; Paniagua, R; Ricote, M; Royuela, M | 1 |
| Hakariya, T; Igawa, T; Kanetake, H; Sakai, H; Shida, Y | 1 |
| Chen, D; Dou, QP; Landis-Piwowar, KR; Li, X; Li, Y; Meng, Y; Reddy, GP; Sarkar, FH; Sheng, S; Yang, H; Yin, S | 1 |
| Chen, ZQ; Li, XJ; Lin, YH; Lu, N; Pan, Y; Zhou, H | 1 |
| Kong, CZ; Zhang, YX | 1 |
| Fang, W; He, C; Heng, W; Li, H; Wu, B; You, J; Zheng, J | 1 |
| Adam, RM; Freeman, MR; Kim, J | 1 |
19 other study(ies) available for sb 203580 and Prostatic Neoplasms
| Article | Year |
|---|---|
Synthesis and biological analysis of prostate-specific membrane antigen-targeted anticancer prodrugs.
Topics: Antigens, Surface; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; Glutamate Carboxypeptidase II; Glutarates; Humans; Ligands; Male; Molecular Targeted Therapy; Prodrugs; Prostatic Neoplasms; Structure-Activity Relationship; Urea | 2010 |
Genome-wide gene expression analysis of a murine model of prostate cancer progression: Deciphering the roles of IL-6 and p38 MAPK as potential therapeutic targets.
Topics: Androgens; Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; Disease Progression; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Imidazoles; Interleukin-6; Male; Mice; p38 Mitogen-Activated Protein Kinases; Prostatic Neoplasms; Pyridines | 2020 |
Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells.
Topics: Antineoplastic Agents; Cell Movement; Diphosphonates; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Exotoxins; Humans; Imidazoles; Interleukin-12; Male; p38 Mitogen-Activated Protein Kinases; Phenotype; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Pyridines; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2013 |
Sesamin inhibits lipopolysaccharide-induced proliferation and invasion through the p38-MAPK and NF-κB signaling pathways in prostate cancer cells.
Topics: Cell Line, Tumor; Cell Proliferation; Cytokines; Dioxoles; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Lignans; Lipopolysaccharides; Male; Neoplasm Invasiveness; Neoplasm Proteins; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Prostatic Neoplasms; Pyridines; Signal Transduction | 2015 |
Tubeimoside-1 induces oxidative stress-mediated apoptosis and G0/G1 phase arrest in human prostate carcinoma cells in vitro.
Topics: Acetylcysteine; Amino Acid Chloromethyl Ketones; Anthracenes; Apoptosis; Caspase 3; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Cinnamates; Cyclin E; Cyclin-Dependent Kinase 2; Dose-Response Relationship, Drug; Endoplasmic Reticulum Stress; G1 Phase; Humans; Imidazoles; JNK Mitogen-Activated Protein Kinases; Male; MAP Kinase Kinase Kinase 5; Membrane Potential, Mitochondrial; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyridines; Reactive Oxygen Species; Resting Phase, Cell Cycle; Saponins; Thiourea; Triterpenes | 2016 |
Prostate specific membrane antigen (PSMA): a novel modulator of p38 for proliferation, migration, and survival in prostate cancer cells.
Topics: Antigens, Surface; Blotting, Western; Cell Line, Tumor; Cell Movement; Cell Survival; Flow Cytometry; Glutamate Carboxypeptidase II; Humans; Imidazoles; Male; Membrane Glycoproteins; p38 Mitogen-Activated Protein Kinases; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Signal Transduction | 2013 |
Translation inhibitors sensitize prostate cancer cells to apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by activating c-Jun N-terminal kinase.
Topics: Activating Transcription Factor 2; Anisomycin; Apoptosis; Apoptosis Regulatory Proteins; Curcumin; Cyclic AMP Response Element-Binding Protein; Cycloheximide; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; Gene Expression Regulation, Enzymologic; Genetic Vectors; Humans; Imidazoles; JNK Mitogen-Activated Protein Kinases; Male; MAP Kinase Kinase Kinase 2; MAP Kinase Kinase Kinases; Membrane Glycoproteins; Mitogen-Activated Protein Kinases; Peptide Fragments; Prostatic Neoplasms; Protein Biosynthesis; Protein Synthesis Inhibitors; Pyridines; TNF-Related Apoptosis-Inducing Ligand; Transcription Factors; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2003 |
p38 MAP kinase modulates Smad-dependent changes in human prostate cell adhesion.
Topics: Adenocarcinoma; Cell Adhesion; DNA-Binding Proteins; Enzyme Induction; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Male; Mitogen-Activated Protein Kinases; Neoplasm Proteins; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Prostatic Neoplasms; Protein Processing, Post-Translational; Protein Transport; Pyridines; Signal Transduction; Smad2 Protein; Smad3 Protein; Trans-Activators; Transforming Growth Factor beta; Tumor Cells, Cultured | 2003 |
[Effects of P2Y receptor activation on prostatic cancer cells requiring ERK1/2 or p38 cascade].
Topics: Adenosine Triphosphate; Cell Line, Tumor; Cell Proliferation; Humans; Imidazoles; Male; MAP Kinase Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplasm Invasiveness; p38 Mitogen-Activated Protein Kinases; Prostatic Neoplasms; Pyridines; Receptors, Purinergic P2; Transfection | 2004 |
[ERK1/2 and p38 kinases are important regulators in P2Y receptor-mediated prostate cancer invasion].
Topics: Cell Line, Tumor; Enzyme Inhibitors; Flavonoids; Humans; Imidazoles; Male; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplasm Invasiveness; p38 Mitogen-Activated Protein Kinases; Prostatic Neoplasms; Pyridines; Receptors, Purinergic P2; Signal Transduction | 2005 |
MAPKAPK2 and HSP27 are downstream effectors of p38 MAP kinase-mediated matrix metalloproteinase type 2 activation and cell invasion in human prostate cancer.
Topics: Adenocarcinoma; Cell Line, Tumor; Enzyme Activation; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Humans; Imidazoles; Intracellular Signaling Peptides and Proteins; Male; Matrix Metalloproteinase 2; Molecular Chaperones; Neoplasm Invasiveness; Neoplasm Proteins; p38 Mitogen-Activated Protein Kinases; Prostatic Neoplasms; Protein Kinases; Protein Serine-Threonine Kinases; Pyridines; Recombinant Fusion Proteins; RNA Interference; RNA, Small Interfering; Signal Transduction; Transfection; Transforming Growth Factor beta | 2006 |
Functional analyses of C13orf19/P38IP in prostate cell lines.
Topics: Apoptosis; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Humans; Imidazoles; Male; p38 Mitogen-Activated Protein Kinases; Prostatic Hyperplasia; Prostatic Neoplasms; Pyridines; RNA, Messenger; RNA, Small Interfering; Transcription Factors; Transfection; Two-Hybrid System Techniques | 2006 |
P38 MAPK protects against TNF-alpha-provoked apoptosis in LNCaP prostatic cancer cells.
Topics: Anthracenes; Apoptosis; Blotting, Western; Cell Line, Tumor; Dose-Response Relationship, Drug; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Humans; Imidazoles; JNK Mitogen-Activated Protein Kinases; Male; p38 Mitogen-Activated Protein Kinases; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyridines; Signal Transduction; Tumor Necrosis Factor-alpha | 2006 |
p38MAPK activation is involved in androgen-independent proliferation of human prostate cancer cells by regulating IL-6 secretion.
Topics: Androgens; Anthracenes; Cell Line, Tumor; Cell Proliferation; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Humans; Imidazoles; Interleukin-6; Male; p38 Mitogen-Activated Protein Kinases; Prostatic Neoplasms; Pyridines; Ritodrine | 2007 |
Maspin augments proteasome inhibitor-induced apoptosis in prostate cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cysteine Proteinase Inhibitors; Cytomegalovirus; Dose-Response Relationship, Drug; Genetic Vectors; Humans; Imidazoles; Leupeptins; Luteolin; Male; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Promoter Regions, Genetic; Prostatic Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Kinase Inhibitors; Pyridines; RNA Interference; RNA, Messenger; RNA, Small Interfering; Serpins; Transcription Factor AP-1; Transcription, Genetic; Transfection | 2007 |
Oxidative stress mediates CoCl(2)-induced prostate tumour cell adhesion: role of protein kinase C and p38 mitogen-activated protein kinase.
Topics: Cell Adhesion; Cell Hypoxia; Cell Line, Tumor; Cobalt; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Imidazoles; Male; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Prostatic Neoplasms; Protein Kinase C; Pyridines; Pyrrolidines; Reactive Oxygen Species; Thiocarbamates | 2007 |
[The role of mitogen-activated protein kinase cascades in inhibition of proliferation in human prostate carcinoma cells by raloxifene: an in vitro experiment].
Topics: Apoptosis; Blotting, Western; Bone Density Conservation Agents; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Enzyme Inhibitors; Flavonoids; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; In Situ Nick-End Labeling; JNK Mitogen-Activated Protein Kinases; Male; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyridines; Raloxifene Hydrochloride; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2008 |
[Activation of p38 and c-Jun NH2-terminal kinase mitogen-activated protein kinases in human prostate carcinoma cell lines with different metastatic potentials].
Topics: Adenosine Triphosphate; Cell Line, Tumor; Humans; Imidazoles; JNK Mitogen-Activated Protein Kinases; Male; Neoplasm Metastasis; p38 Mitogen-Activated Protein Kinases; Prostatic Neoplasms; Purinergic P2 Receptor Agonists; Pyridines; Signal Transduction; Suramin | 2001 |
Activation of the Erk mitogen-activated protein kinase pathway stimulates neuroendocrine differentiation in LNCaP cells independently of cell cycle withdrawal and STAT3 phosphorylation.
Topics: Cell Cycle; Cell Differentiation; DNA-Binding Proteins; Enzyme Activation; Epidermal Growth Factor; Heparin-binding EGF-like Growth Factor; Humans; Imidazoles; Intercellular Signaling Peptides and Proteins; Interleukin-6; Male; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Neurosecretory Systems; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Prostatic Neoplasms; Pyridines; STAT3 Transcription Factor; Trans-Activators; Tumor Cells, Cultured | 2002 |